Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCOTT: Autologous HSCT for Liver Transplant Tolerance
NCT02549586Phase 2Completed
- Start
- Dec 2015
- Primary completion
- Apr 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in Liver transplant rejection. Primary endpoint: Number of patients who develop tolerance post autologous HSCT. Started Dec 2015; status: completed.
02
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT02549586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02549586.